OBJECTIVE To investigate the clinical efficacy and safety of Shouhui tongbian capsule combined with linaclotide in the treatment of constipation-predominant irritable bowel syndrome （IBS-C）. METHODS A total of 97 IBS-C patients admitted to Nanyang First People’s Hospital between March 2022 and February 2024 were enrolled. Using a random number table method， patients were divided into control group （n＝46） and observation group （n＝51）. On the basis of routine treatment， the control group was given Linaclotide capsules orally， while the observation group received Linaclotide capsules combined with Shouhui tongbian capsule orally. The treatment course for both groups was 4 weeks. Clinical efficacy， Irritable Bowel Syndrome Severity Scale （IBS-SSS）， stool frequency， Bristol Stool Form Scale （BSFS）， Irritable Bowel Syndrome Quality of Life Questionnaire （IBS-QOL） score， gastrointestinal hormone levels， anorectal manometry parameters， and the occurrence of adverse reactions were compared between the two groups. RESULTS Two patients in the control group and three patients in the observation group dropped out due to adverse reactions. The effective rate in the observation group （87.50%） was significantly higher than that in the control group （68.18%）（P＜0.05）. Compared with pre-treatment， both groups showed significant increase in post-treatment stool frequency， BSFS score， serum substance P， and motilin levels. Conversely， IBS-SSS scores， IBS-QOL scores， serum vasoactive intestinal peptide levels， anal-rectal pressure difference， rectal compliance， rectal sensation threshold， and defecation threshold were significantly reduced （P＜0.05）. The observation group demonstrated superior outcomes to the control group （excluding rectal sensation and defecation thresholds， P＜0.05）. No significant difference in the incidence of adverse reactions was observed between the two groups （P＞0.05）. CONCLUSIONS Compared with linaclotide monotherapy， Shouhui tongbian capsule combined with linaclotide improves gastrointestinal hormone function and anorectal manometry parameters in IBS-C patients， alleviates clinical symptoms， improves quality of life， and exhibits favorable safety.